MSB gets Fast Track from FDA

3 ธ.ค. 2020

Looks like price is respecting trendline / uptrend.

Price is within range. Needs to break above resistance and stay above for bullish confirmation.

Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).

Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L

2 ม.ค. 2021

บันทึกช่วยจำ

Sadly bad news came out and the trend was invalidated - trading just above 78.6% area. I'm in quite a rough drawdown on my positions but you live and you learn. Biotcech stocks are highly risky!